Leveraging Patient-Reported Outcomes for Drug Development and Commercial Success
How to harness the power of patient-reported outcomes to drive clinical research and commercial gains
From refining clinical study design to informing HTA reviews and commercial decision-making, increasingly influential patient-reported outcome (PRO) data is in demand across the pharma business. So, what are the current approaches and tools for efficiently collecting and communicating the PRO data that specifically meets the needs of clinical research planners, payers, and HCPs?
Companies
AbbVie, Amgen, Novartis, Lilly, GSK, AstraZeneca, Regeneron, Sanofi, UCB, Pfizer, Merck & Co., Jazz Pharmaceuticals, Genentech, Sunovion, Takeda, Eisai, Bayer, Shire (Takeda), CTI BioPharma, Boehringer Ingelheim, Ironwood Pharmaceuticals, EMD Serono, Johnson & Johnson Innovative Medicine, Actelion, Sumitomo Pharma America
- Subject synopsis
- Research methodology and objectives
- Experts interviewed
- Key research objectives
- Key insights summary
- Issues and insights
- The current impact of PROs on drug research and development
- Issue summary
- Questions
- Key insights
- Supporting quotes
- Intelligence exhibits
- Challenges of deploying PROs in drug research and development
- Issue summary
- Questions
- Key insights
- Supporting quotes
- Intelligence exhibits
- Future opportunities for PROs to drive product development and market access
- Issue summary
- Questions
- Key insights
- Supporting quotes
- Intelligence exhibits
- Further Reading
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook